Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy
- Citation:
- Am J Surg Pathol vol 45 (3) 384-393
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 2393
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- from Celgene (CALGB 50803), GlaxoSmithKline (CALGB 50901)
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233329, UG1CA233339
- Corr. Author:
- Authors:
- Aliyah R. Sohani Matthew J. Maurer Sharmila Giri Brandelyn Pitcher Amy Chadburn Jonathan W. Said Nancy L. Bartlett Myron S. Czuczman Peter Martin Cara A. Rosenbaum Sin-Ho Jung John P. Leonard Bruce D. Cheson Eric D. Hsi
- Networks:
- CAPITAL, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY158, NY018
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901
- Phases:
- 2
- Keywords:
- follicular lymphoma, BCL6, CD10, Ki67 proliferation index, prognostic biomarkers